Molecular Mechanisms and Diagnostic Innovations in HPV-Associated Head and Neck Squamous Cell Carcinomas: Insights into Integration, Epigenetic Modifications, and Biomarker Applications DOI Creative Commons
Geetha Shanmugam, Gnanaprakash Jeyaraj, Koustav Sarkar

et al.

Oral Oncology Reports, Journal Year: 2024, Volume and Issue: 13, P. 100710 - 100710

Published: Dec. 27, 2024

Language: Английский

Current and Emerging Diagnostic, Prognostic, and Predictive Biomarkers in Head and Neck Cancer DOI Creative Commons
Hänel W. Eberly, Bao Y. Sciscent, F. Jeffrey Lorenz

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(2), P. 415 - 415

Published: Feb. 10, 2024

Head and neck cancers (HNC) are a biologically diverse set of that responsible for over 660,000 new diagnoses each year. Current therapies HNC require comprehensive, multimodal approach encompassing resection, radiation therapy, systemic therapy. With an increased understanding the mechanisms behind HNC, there has been growing interest in more accurate prognostic indicators disease, effective post-treatment surveillance, individualized treatments. This chapter will highlight commonly used studied biomarkers head squamous cell carcinoma.

Language: Английский

Citations

10
Assessing the feasibility of a multimodal liquid biopsy for the diagnosis of HPV-associated oropharyngeal squamous cell carcinoma DOI
James S. Lewis, Saskia Naegele, Vasileios Efthymiou

et al.

American Journal of Clinical Pathology, Journal Year: 2024, Volume and Issue: 161(6), P. 570 - 578

Published: Feb. 13, 2024

Abstract Objectives In this feasibility study, we explored the combined use of circulating tumor human papillomavirus (HPV) DNA (ctHPVDNA) and HPV serology as diagnostic tests for HPV-associated oropharyngeal squamous cell carcinoma (OPSCC). Methods Among patients with research-banked serum or plasma at diagnosis, IgG antibodies to oncoproteins from types 16, 18, 31, 33, 35, 45, 52, 58 were detected multiplex serology. Positivity 16 was defined based on detection combinations anti-E6, E1, E2, E7 other high-risk anti-E6 anti-E7. Circulating by custom digital droplet polymerase chain reaction (ddPCR) assays 45. p16 immunohistochemistry RNA in situ hybridization (ISH) using a cocktail 18 performed tissue. Results Of 75 patients, 67 (89.3%) (p16 ISH positive) 8 (10.7%) HPV-independent. All HPV-independent seronegative negative ctHPVDNA (100% specificity). Serology positive 53 (79.1%) while ddPCR 59 (88.6%) patients. Requiring both be resulted sensitivity 50 (74.6%) combining (either improved 62 (92.6%) 67. Conclusions Compared ISH, are sensitive highly specific biomarkers OPSCC time presentation.

Language: Английский

Citations

4
Individualisierung und Standardisierung in der Kopf-Hals-Pathologie DOI Creative Commons
Andreas Loth, Peter J. Wild

HNO, Journal Year: 2025, Volume and Issue: unknown

Published: April 16, 2025

Zusammenfassung Individualisierung und Standardisierung sind scheinbar widersprüchliche Anforderungen in der Medizin. In Tumorbehandlung von Kopf-Hals-Karzinomen haben beide Begriffe direkten Einfluss auf die Diagnostik, welche üblicherweise pathologischen Instituten durchgeführt wird. Im vorliegenden Referat wird das Spannungsfeld zwischen technischen Untersuchungen, regulatorischen Anforderungen, strukturellen Änderungen durch Digitalisierung dem Einzug personalisierten Medizin beleuchtet. Ziel ist zum einen, ein Verständnis Herausforderungen den interdisziplinären Austausch zu fördern, anderen sollen HNO-Arzt ganz praktisch gängigen Untersuchungen nähergebracht werden. Am Beispiel Pathologie lässt sich so schlussendlich zeigen, dass Verfahren einer Verbesserung individuellen Behandlung dient. Zugleich lassen aber auch ablesen: Trotz umfassender Regularien sowie Laborumgebung mit digitaler Unterstützung sehr zeit- kostenaufwendig. Sollen ähnliche Standardisierungsansätze beispielsweise einem operativen Umfeld wie HNO-Chirurgie umgesetzt werden, darf Aufwand aufgrund „menschlichen Komponente“ als gleichwertig oder höher eingeschätzt

Citations

0
Blood-based screening for HPV-associated cancers DOI Creative Commons

Dipon Das,

Shun Hirayama,

Ling Aye

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 5, 2024

Abstract Background HPV-associated oropharyngeal cancer (HPV+OPSCC) is the most common in United States yet unlike cervical lacks a screening test. HPV+OPSCCs are presumed to start developing 10-15 years prior clinical diagnosis. Circulating tumor HPV DNA (ctHPVDNA) sensitive and specific biomarker for HPV+OPSCC. Taken together, blood-based HPV+OPSCC may be feasible Methods We developed an whole genome sequencing assay, HPV-DeepSeek, with 99% sensitivity specificity at 28 plasma samples from patients collected 1.3-10.8 diagnosis along 1:1 age gender-matched controls were run on HPV-DeepSeek serology assay. Results 22/28 (79%) of cases 0/28 screened positive 100% detection within four maximum lead time 7.8 years. next applied machine learning model classifying 27/28 (96%) 10 Plasma-based PIK3CA gene mutations, viral integration events used orthogonally validate 68% (19/28) cohort having multiple signals detected. Molecular fingerprinting genomes was performed across demonstrating that each unique, ruling out contamination. In blocks (15/28), molecular confirming same time. Conclusions demonstrate accurate cancers times up before doing so, highlight enormous potential ctDNA-based screening.

Language: Английский

Citations

3
The Next Chapter in Cancer Diagnostics: Advances in HPV-Positive Head and Neck Cancer DOI Creative Commons

Antea Kršek,

Lara Batičić,

Tamara Braut

et al.

Biomolecules, Journal Year: 2024, Volume and Issue: 14(8), P. 925 - 925

Published: July 30, 2024

Human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC), particularly oropharyngeal (OPSCC), is an increasingly prevalent pathology worldwide, especially in developed countries. For diagnosing HPV HNSCC, the combination of p16 immunohistochemistry (IHC) polymerase chain reaction (PCR) offers high sensitivity specificity, with IHC being a reliable initial screen PCR confirming presence. Advanced techniques like next-generation sequencing (NGS) RNA-based assays provide detailed insights but are primarily used research settings. Regardless status, standard oncological treatments currently include surgery, radiation, and/or chemotherapy. This conventional approach does not account for typically better prognosis HPV-positive HNSCC patients, leading to increased chemo/radiation-induced secondary morbidities reduced quality life. Therefore, it crucial identify detect positivity other molecular characteristics personalize treatment strategies. comprehensive review aims summarize current knowledge on various detection evaluate their advantages disadvantages, focus developing methodologies new biomarkers HNSCC. The discusses direct indirect examination tumor tissue, DNA- techniques, protein-based markers, liquid biopsy potentials, immune-related epigenetic novel biomarkers, emerging technologies, providing overall insight into state knowledge.

Language: Английский

Citations

1
Detection of serum biomarkers of HPV-16 driven oropharynx and oral cavity cancer in Brazil DOI
Laura Sichero, Milena Giulia Gonçalves, Fabiana Bettoni

et al.

Oral Oncology, Journal Year: 2023, Volume and Issue: 149, P. 106676 - 106676

Published: Dec. 26, 2023

Language: Английский

Citations

3
Molecular Mechanisms and Diagnostic Innovations in HPV-Associated Head and Neck Squamous Cell Carcinomas: Insights into Integration, Epigenetic Modifications, and Biomarker Applications DOI Creative Commons
Geetha Shanmugam, Gnanaprakash Jeyaraj, Koustav Sarkar

et al.

Oral Oncology Reports, Journal Year: 2024, Volume and Issue: 13, P. 100710 - 100710

Published: Dec. 27, 2024

Language: Английский

Citations

0